Nitika Sharma

Nano-enhanced immunotherapy: Targeting the immunosuppressive tumor microenvironment

Transferrin receptor targeting chimeras for membrane protein degradation

Transferrin receptor 1 upregulation in primary tumor and downregulation in benign kidney is associated with progression and mortality in renal cell carcinoma patients

Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade